Well if this CGF166 trial even has a small percent of hope and does not cause any harm from the genes, then this will open up more novel treatments. The thing is the drug companies usually run from "novel" treatments because they are high risk and hence low returns on profit. But if the CGF166 delivery works, it may motivate more competition and more treatments. Maybe a treatment in the adenovirus to create mitosis and transdifferentiation at the same time. If this CGF166 causes harm or fails miserably, then companies will run for the exits and probably only our grandchildren will get a cure
I wish more countries with less Big Pharma would get into this...such as India, Japan or China. Their governments do more to get research into testing much quicker and way cheaper. For example, Japan has already started stem cell trails for retinal problems in eyes. The Japanese invented iPSC. India also has done some clinical trials with stem cells for corneas. So many countries are going faster when they don't have to wait for a rich company to find a profit in our suffering. So perhaps if Novartis runs for the exit...maybe Japan or India will put resources on it.
The Genvec Trial is still a proof of concept trial and it's not likely to enter any clinical application in its form.
If they coud reach the aims:
-save delivery to inner ear
-regeneration and enhancement in vestibular
-regeneration and enhancement in hearing
it's something nobody did before.
If it's possible, they need to perfect any aspect of this therapy to really help people and
to get the ok of FDA, because the therapy must be better than what's on the market, andprobably
CI does help people more at least.
It's all speculation, but I think if researchers learn and know how reactivate the regeneration cycle, they will
optimize the outcomes and the procedure to apply the drug.
Dr. Hinrich Staecker does a pioneer thing, many of very good reseachers don't believe in a real success
in this kind of therapy, because nobody was able to replicate this trial in other labs.
So maybe they optimized it already and disclosed the abstracts or the strategy is something different.
I guess there must be a substance, without Novartis wouldn't give their name for.
But exciting times are coming, I put many hopes in the LGR5 (Audion Therapeutics) approach.